#1 Clinical Trials Search in Europe

Tx200-Tr101

Recent clinical trials are exploring the potential of TX200-TR101, an innovative autologous antigen-specific Chimeric Antigen Receptor T Regulatory Cell (CAR-Treg) therapy, in preventing kidney transplant rejection. This groundbreaking treatment aims to improve outcomes for patients receiving living donor kidney transplants by enhancing the body’s natural regulatory mechanisms. The ongoing studies focus on evaluating the safety, tolerability, and long-term effects of TX200-TR101 in transplant recipients.

Table of Contents

What is TX200-TR101?

TX200-TR101 is a new type of medicine being developed to help prevent the rejection of kidney transplants in patients receiving a kidney from a living donor[1]. It’s an innovative therapy that uses the patient’s own immune cells, specifically a type called T regulatory cells (Tregs), which have been modified to help protect the transplanted kidney[1].

This therapy is classified as an autologous antigen-specific chimeric antigen receptor T regulatory cell therapy. Let’s break down what this means:

  • Autologous: The cells used in the therapy come from the patient’s own body.
  • Antigen-specific: The cells are designed to recognize specific markers (antigens) on the transplanted kidney.
  • Chimeric antigen receptor (CAR): The patient’s cells are genetically modified to have a special receptor that helps them target the transplanted kidney.
  • T regulatory cell therapy: The treatment uses a type of immune cell (T regulatory cells or Tregs) that helps control the immune response and prevent rejection.

How Does TX200-TR101 Work?

TX200-TR101 works by using the patient’s own modified immune cells to help protect the transplanted kidney from rejection[1]. Here’s a simplified explanation of the process:

  1. Some of the patient’s T regulatory cells are collected.
  2. These cells are genetically modified in a laboratory to create a special receptor (CAR) that can recognize the transplanted kidney.
  3. The modified cells (now called TX200-TR101) are grown to increase their numbers.
  4. After the kidney transplant, the TX200-TR101 cells are given back to the patient through an intravenous infusion (a drip into a vein)[1].
  5. These modified cells then work to prevent the patient’s immune system from attacking and rejecting the new kidney.

Clinical Trials

TX200-TR101 is currently being studied in clinical trials to evaluate its safety and effectiveness. The main study is called STEADFAST, which stands for “A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients”[1].

The main goals of this study are:

  • To assess the short-term safety and tolerability of TX200-TR101 in the first 28 days after infusion[1].
  • To evaluate how well TX200-TR101 prevents acute rejection of the transplanted kidney[1].
  • To see if patients receiving TX200-TR101 can reduce their use of other immunosuppressive medications over time[1].
  • To check if the TX200-TR101 cells can be found in the transplanted kidney, which would show they are working where needed[1].

Who Can Receive TX200-TR101?

As TX200-TR101 is still in clinical trials, it’s not yet available for general use. The current study has specific criteria for who can participate. Some key points include:

  • Patients must be between 18 and 70 years old[1].
  • They must have end-stage renal disease (ESRD) and be waiting for a kidney transplant from a living donor[1].
  • They should not have had any previous organ transplants[1].
  • They should not have certain types of kidney diseases that have a high risk of recurring in the transplanted kidney[1].

Potential Benefits

While the full benefits of TX200-TR101 are still being studied, researchers hope it will offer several advantages:

  • Better prevention of kidney transplant rejection[1].
  • Potential reduction in the need for other immunosuppressive medications, which can have significant side effects[1].
  • Improved long-term survival of the transplanted kidney[1].

Safety and Side Effects

As TX200-TR101 is a new therapy, one of the main goals of the current clinical trial is to evaluate its safety and potential side effects[1]. The researchers are closely monitoring:

  • Any adverse events (side effects) that occur within 28 days of receiving TX200-TR101[1].
  • Long-term safety outcomes up to 84 weeks after treatment[1].
  • The occurrence of infections, particularly reactivation of certain viruses (BKV, EBV, and CMV)[1].
  • Any development of cancers[1].

Long-Term Follow-Up

To fully understand the long-term effects of TX200-TR101, a separate study called STEADFAST Long Term is being conducted[2]. This study will follow patients who received TX200-TR101 in the initial trial for an extended period. The main goals of this long-term study are:

  • To assess the overall survival of patients who received TX200-TR101[2].
  • To monitor for any serious side effects that might occur over time[2].
  • To evaluate how well the transplanted kidney continues to function[2].
  • To check for any signs of chronic rejection or other long-term complications[2].

This long-term follow-up is crucial to ensure the safety and effectiveness of TX200-TR101 beyond the initial treatment period.

Aspect Details
Drug Name TX200-TR101
Type of Therapy Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell (CAR-Treg) Therapy
Administration Intravenous infusion
Target Condition Prevention of kidney transplant rejection
Study Phase Phase I/IIa
Primary Objectives Evaluate safety and tolerability within 28 days post-infusion
Secondary Objectives Assess long-term safety, graft-related outcomes, immunosuppression reduction, and therapy localization
Follow-up Duration Initial study: 84 weeks; Long-term follow-up study: Extended period
Key Endpoints Incidence of adverse events, graft rejection rates, graft function, survival rates

FAQ

  • What is TX200-TR101? TX200-TR101 is an advanced cell therapy that uses a patient's own regulatory T cells, which have been modified to express a Chimeric Antigen Receptor (CAR). This therapy is designed to help prevent rejection in kidney transplant patients.
  • How is TX200-TR101 administered? TX200-TR101 is administered as a solution for infusion through intravenous use. This means it is given directly into the patient's bloodstream.
  • Who is eligible for the TX200-TR101 clinical trials? The main study includes adults aged 18-70 with end-stage renal disease (ESRD) who are waiting for a kidney from a living donor. Participants must not have had a prior organ transplant and must meet other specific health criteria.
  • What are the main goals of the TX200-TR101 clinical trials? The primary goals are to evaluate the safety and tolerability of TX200-TR101 in the short term (within 28 days of infusion) and to assess its long-term effects on graft rejection, graft function, and overall patient survival.
  • How long will patients be followed after receiving TX200-TR101? There are two studies: an initial study lasting 84 weeks and a long-term follow-up study. The long-term study will continue to monitor patients who received TX200-TR101 in the initial trial to assess its safety and effectiveness over an extended period.

Ongoing Clinical Trials on Tx200-Tr101

  • Long-Term Follow-Up Study of TX200-TR101 for Patients with Kidney Transplant Rejection

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium The Netherlands

  • Study on the Safety of TX200-TR101 for Preventing Kidney Transplant Rejection in Patients Receiving a Living Donor Transplant

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium The Netherlands

Glossary

  • Autologous: Using cells or tissues obtained from the same individual. In this case, TX200-TR101 uses the patient's own T cells.
  • Chimeric Antigen Receptor (CAR): A specially engineered receptor added to immune cells (like T cells) that allows them to recognize specific proteins on other cells.
  • T Regulatory Cells (Tregs): A type of immune cell that helps control the immune system's response and prevent it from attacking the body's own tissues.
  • End-Stage Renal Disease (ESRD): Advanced kidney failure requiring dialysis or a kidney transplant for survival.
  • Graft: In this context, refers to the transplanted kidney.
  • Biopsy-Confirmed Acute Rejection (BCAR): A diagnosis of transplant rejection confirmed by examining a small sample of the transplanted kidney tissue.
  • Immunosuppression: The use of drugs to reduce the body's immune response, typically to prevent rejection of a transplanted organ.
  • Estimated Glomerular Filtration Rate (eGFR): A measure of how well the kidneys are filtering waste from the blood.
  • Donor-Specific Antibodies (DSA): Antibodies in the recipient's blood that react specifically against the donor's tissues.
  • Treatment-Emergent Adverse Events (TEAEs): Side effects or complications that occur after starting a treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-tx200-tr101-for-preventing-kidney-transplant-rejection-in-patients-receiving-a-living-donor-transplant/
  2. http://clinicaltrials.eu/trial/long-term-follow-up-study-of-tx200-tr101-for-patients-with-kidney-transplant-rejection/